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Background: Insulin-like growth factor 1 (IGF1) is an important determinant of muscle mass because it
promotes growth and suppresses protein degradation. IGF1 is decreased in rheumatoid arthritis and
juvenile idiopathic arthritis because its synthesis is inhibited by inflammation. In parallel, glucocorticoids
induce IGF1 resistance and add to muscle degradation.
Objective: To investigate the influence of anti-tumour necrosis factor antibody treatment (anti-TNF) with
adalimumab on levels of myoglobin (degradation marker) and IGF1 in patients with rheumatoid arthritis
with and without prednisolone treatment.
Methods: Subcutaneous adalimumab was given to 32 patients with longstanding rheumatoid arthritis (16
with and 16 without prednisolone) in a longitudinal study. IGF1, IGF1 binding protein 1 (IGFBP-1), IGFBP-
3, and myoglobin were measured by enzyme linked immunosorbent assay.
Results: Rheumatoid patients had normal serum myoglobin. Patients on prednisolone had higher
myoglobin than patients not receiving prednisolone, indicating increased muscle degradation. On
treatment with anti-TNF, myoglobin levels did not change in either patient group. Serum IGF1 was
increased in patients with v without prednisolone, indicating IGF1 resistance (mean (SEM): 221 (23) v 122
(14) mg/l, p,0.001). Adalimumab treatment decreased the raised IGF1 levels in patients with
prednisolone, so that after 12 weeks of treatment they reached the level of patients without prednisolone.
Serum IGFBP-1 and IGFBP-3 did not differ in the two groups, and anti-TNF did not change these
concentrations.
Conclusions: Anti-TNF antibody treatment over 12 weeks improved glucocorticoid induced IGF1
resistance without influencing myoglobin and IGF1 binding proteins. Thus, in rheumatoid patients on
glucocorticoids with generally decreased muscle mass anti-TNF treatment with adalimumab has
favourable effects.
M
any patients with rheumatoid arthritis suffer from
decreased muscle function and loss of body cell
mass.1–3 The mechanisms involved are unknown at
present. High levels of tumour necrosis factor (TNF) and
parallel glucocorticoid treatment were thought to be impor-
tant elements in these alterations in rheumatoid patients.4 5
One key element in maintaining muscle mass is insulin-
like growth factor 1 (IGF1), by promoting muscle growth and
suppressing muscle degradation.6 IGF1 has additional
favourable effects on TNF induced cartilage degradation.7 8
Furthermore, TNF—a major proinflammatory cytokine in
rheumatoid arthritis—inhibits synthesis of IGF1 from liver
cells,9 10 and it also inhibits IGF1 mediated anabolic effects on
peripheral tissue.11 From these data, one would expect an
increase of serum IGF1 levels during anti-TNF treatment in
patients with rheumatoid arthritis, which has never been
investigated.
In addition, parallel glucocorticoid treatment may influ-
ence the effects of anti-TNF treatment because glucocorti-
coids per se can lead to IGF1 resistance.12 IGF1 resistance has
been demonstrated during glucocorticoid treatment by an
increase in serum IGF1.12 13 A glucocorticoid related increase
of IGF1 in the presence of increased muscle degradation is a
marker of muscle IGF1 resistance. A similar phenomenon
exists with respect to insulin,14 in that glucocorticoids
increase insulin resistance. Furthermore, patients with
rheumatoid arthritis show insulin resistance, which is
improved during anti-TNF treatment.15
As serum levels of IGF1 and its most important binding
proteins, IGF1 binding protein 1 (IGFBP-1) and IGFBP-3,
have never been studied during anti-TNF treatment in
rheumatoid patients, we aimed to shed light on these
variables during a 12 week course of adalimumab treatment.
We also investigated IGF1 resistance during glucocorticoid
treatment.
METHODS
Patients, adalimumab treatment, and blood samples
The study involved the administration of the human
monoclonal antibody adalimumab (Abbott SpA,
Campoverde di Aprilia, Italy) to 32 white patients with
rheumatoid arthritis fulfilling the American College of
Rheumatology (ACR) criteria for the disease.16 The patients
were selected according to the inclusion criteria of the
adalimumab research in active rheumatoid arthritis study
(ReAct). In all, 16 patients received parallel prednisolone,
while the other 16 did not receive parallel prednisolone and
Abbreviations: ACR, American College of Rheumatology; EULAR,
European League Against Rheumatism; IGF1, insulin-like growth factor
1; ReAct, Adalimumab Research in Active Rheumatoid Arthritis study;
TNF, tumour necrosis factor
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had not been treated with prednisolone for at least six
months. Most patients were also given additional metho-
trexate (the dose remained stable throughout this study), but
no other immunosuppressive drugs. The baseline character-
istics of patients are given in table 1.
Patients were assigned to receive single self injections of
adalimumab subcutaneously, 40 mg every other week.
Efficacy assessments included ACR and EULAR response
criteria (carried out by FA and PS-P).17 A baseline blood
sample was taken one to two weeks before the start of
adalimumab treatment. Anti-TNF antibodies were infused on
weeks 0, 2, 4, 6, 8, 10, and 12. For this study, patients were
investigated clinically and blood was drawn between 08:00
and 09:00 in the morning when the patients visited the
outpatient clinic on the baseline day, and in weeks 2, 6, and
12. The blood was immediately centrifuged and serum was
stored on 280 C˚. The ethics committee of L Sacco University
Hospital, Italy, approved the study.
Laboratory indices
We used enzyme immunometric assays for the quantitative
determination of serum levels of interleukin 6 (IL6) (high
sensitivity Quantikine, R&D Systems, Minneapolis,
Minesota, USA), myoglobin (Life Diagnostics Inc, West
Chester, Pennsylvania, USA; normal range according to the
manufacturer 12 to 90 ng/ml), IGF1 (IDS, Bolden, UK;
normal range according to the manufacturer of subjects aged
60 years: 30 to 200 mg/l), IGFBP-1 (Oy Medix Biochemica,
Kauniainen, Finland), and IGFBP-3 (Biosource Europe,
Nivelles, Belgium). Intra-assay and interassay coefficients
of variation for all tests were below 10%.
Statistical analysis
Medians between different groups were compared by the
non-parametric Mann–Whitney test (SPSS/PC, Advanced
Statistics, V11.5.1, SPSS Inc, Chicago, Illinois, USA). A
decrease or increase in a variable over time (during anti-
TNF treatment) was tested using the non-parametric
Friedman test (SPSS). An interrelation between two variables
was tested by the non-parametric Spearman rank correlation
analysis (SPSS). A probability (p) value ,0.05 was the
significance level.
RESULTS
Anti-inflammatory effects of adalimumab treatment
Adalimumab treatment had excellent anti-inflammatory
effects in patients with rheumatoid arthritis with or without
glucocorticoids, as investigated by the number of swollen
Table 1 Characteristics of patients under investigation
All patients
Patients without
glucocorticoids
Patients with
glucocorticoids
Number 32 16 16
Age (years) 59.6 (2.1) 55.2 (2.8)* 64.0 (2.8)
Sex (F/M) 30/2 (93.8/6.25) 15/1 (93.8/6.25) 15/1 (93.8/6.25)
Disease duration (years) 6.9 (1.1) 5.9 (1.6) 7.9 (1.5)
Body mass index (kg/m2) 22.5 (0.6) 22.8 (0.8) 22.3 (0.8)
Baseline ESR (mm/1st hour) 27.7 (3.0) 30.6 (4.8) 24.8 (3.7)
Baseline C reactive protein (mg/l) 14.5 (28.9) 13.1 (4.3) 15.9 (4.0)
Baseline serum IL6 (pg/ml) 27.7 (7.1) 21.6 (7.4) 33.9 (12.2)
Positive for rheumatoid factor 30 (93.8%) 15 (93.8%) 15 (93.8%)
Positive for antinuclear antibodies 2 (6.25%) 1 (6.25%) 1 (6.25%)
Baseline swollen joint score (points) 8.9 (0.4) 8.8 (0.7) 9.1 (0.6)
Baseline tender joint score (points) 10.0 (0.5) 10.5 (0.8) 9.5 (0.5)
Baseline DAS28 (points) 5.5 (0.1) 5.6 (0.2) 5.3 (0.2)
Additional treatment
Prednisolone 16 (50.0%) 0 (0.0%) 16 (100.0%)
Mean daily prednisolone (mg) 2.3 (0.4) 0.0 (0.0) 4.6 (0.2)
Methotrexate 30 (93.8%) 15 (93.8%) 15 (93.8%)
Mean weekly methotrexate dose (mg) 8.0 (0.7) 8.3 (0.9) 7.7 (1.0)
NSAIDs 27 (84.4%) 15 (93.8%) 12 (75.0%)
Chloroquine/hydroxychloroquine 3 (9.4%) 1 (6.25%) 2 (12.5%)
Values are means (SEM) or n (%).
*p,0.01 v patients with glucocorticoids. No other variables were different between patients with and without
glucocorticoid treatment. No patient received azathioprine, leflunomide, ciclosporine A, or sulfasalazine.
DAS28, joint disease activity score; ESR, erythrocyte sedimentation rate; F, female; IL6, interleukin 6; M, male;
NSAID, non-steroidal anti-inflammatory drug.
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Figure 1 Serial measurement of serum myoglobin in patients with
rheumatoid arthritis. Black symbols represent data from patients on
prednisolone; white symbols represent data from patients not receiving
prednisolone. Error bars = SEM. *p,0.05; p,0.005; `p,0.001 for
the difference of medians v patients without prednisolone. The Friedman
p values show whether values changed during the treatment.
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joints, the number of tender joints, patients’ global assess-
ment of pain, and serum levels of IL6 (table 2). It seemed that
these effects were more marked in patients who were not
receiving glucocorticoids (table 2).
Influence of glucocorticoid treatment on muscle
degradation and effects of adalimumab
Baseline serum myoglobin levels were significantly higher in
patients on prednisolone than in patients not receiving
glucocorticoids (fig 1). This indicates a higher degree of
muscle degradation in patients on glucocorticoids. After
controlling for age, this difference remained statistically
significant at weeks 2 and 12 (but not at baseline or week 6).
During the course of anti-TNF treatment, myoglobin levels
remained stable in all patients, whether or not they were
receiving prednisolone (fig 1). Anti-TNF did not change the
myoglobin levels, which may indicate that TNF is not the
main player in this glucocorticoid induced phenomenon.
Influence of glucocorticoid treatment on serum IGF1
and the effects of adalimumab
Patients on prednisolone had markedly higher serum IGF1
levels than those not receiving prednisolone (fig 2A), even
though the former were somewhat older and a lower serum
IGF1 would be expected (table 1). This was particularly
evident at baseline, where serum IGF1 values exceeded the
normal age related range given by the manufacturer (30 to
200 mg/l) in more than half the patients on prednisolone. In
the presence of increased muscle degradation (myoglobin
release), this phenomenon is called IGF1 resistance.
During the course of anti-TNF treatment, serum IGF1
values did not change markedly in patients not receiving
prednisolone (fig 2B). However, in patients who were
receiving prednisolone the raised IGF1 values decreased on
average by more than 50 mg/l (fig 2B). The decrease was
statistically significant (Friedman test, fig 2B). After
12 weeks of adalimumab treatment, serum IGF1 values were
not different between the two groups (fig 2B), which
indicates normalisation of IGF1 resistance.
Influence of glucocorticoid treatment on IGF1 binding
proteins and effects of adalimumab
At baseline, concentrations of the two major binding proteins
of IGF-1, IGFBP-1 and IGFBP-3, did not differ in patients
receiving or not receiving glucocorticoid treatment (data not
shown). The values remained stable throughout the course of
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Figure 2 Serum concentrations of insulin-like growth factor 1 (IGF1) at baseline and during the course of anti-TNF treatment with adalimumab. (A)
Serum IGF1 at baseline as given by box plots in patients with and without glucocorticoid treatment. The boundary of the box closest to zero indicates
the 25th centile, the line within the box marks the median, and the boundary of the box farthest from zero indicates the 75th centile. Whiskers (error
bars) above and below the box indicate the 90th and 10th centiles. (B) Serial measurements of serum IGF1 during the course of anti-TNF treatment in
patients receiving (white symbols) or not receiving (black symbols) prednisolone. Data are means, error bars = SEM. p,0.01; `p,0.001 for the
comparison of medians v patients not receiving prednisolone. The Friedman p values show whether values changed during the treatment (that is, there
was a significant decrease in glucocorticoid treated patients).
Table 2 Response indices during 12 weeks of adalimumab treatment
Number of swollen
joints*
Number of tender
joints*
Pain, patient’s global
assessment* Serum IL6 (pg/ml)*
Baseline 8.8 (0.7) [9.1 (0.6)] 10.5 (0.8) [9.5 (0.5)] 54.8 (4.5) [54.8 (3.7)] 21.6 (7.4) [33.9 (12.2)]
Week 2 7.3 (0.9) [7.0 (0.7)] 9.6 (0.7) [8.1 (0.5)] 40.8 (3.5) [40.7 (5.3)] 4.1 (1.8) [7.0 (1.8)]
Week 6 4.3 (0.9) [4.3 (0.6)] 7.5 (0.80) [6.5 (0.7)] 32.3 (3.8) [38.5 (3.8)] 8.7 (5.3) [5.5 (2.1)]
Week 12 2.8 (0.5) [3.4 (0.6)] 6.1 (0.5) [5.4 (0.7)] 23.3 (3.7) [25.2 (4.7)] 2.9 (0.9) [13.8 (8.5)]
Data are mean (SEM). Data on patients receiving glucocorticoid treatment are given in square brackets.
*p,0.003, indicating a decrease as assessed by the Friedman test.
IL6, interleukin 6.
Anti-TNF and IGF1 in rheumatoid arthritis 303
www.annrheumdis.com
adalimumab treatment (data not shown). Adalimumab
treatment did not affect the serum levels of these binding
proteins (data not shown).
Influence of IL6 and drug treatment on IGF1 and its
binding proteins
There was no correlation between serum levels of IGF1 and
IL6 in patients receiving or not receiving prednisolone (data
not shown), neither was there a correlation between C
reactive protein or erythrocyte sedimentation rate and serum
IGF1 (data not shown).
In patients on prednisolone, serum IL6 correlated positively
with serum IGFBP-1 in week 2 (RRank = 0.500, p = 0.048), in
week 6 (RRank = 0.598, p = 0.015), and in week 12
(RRank = 0.797, p,0.001). The positive correlation increased
during adalimumab treatment, becoming evident at much
lower levels of IL6 (table 2). However, no such correlation
was present in patients not receiving prednisolone (data not
shown). IL6 did not correlate with IGFBP-3 in either patient
group. Furthermore, no correlation was found between IGF1,
IGFBP-1, or IGFBP-3 and the intake of non-steroidal anti-
inflammatory drugs or chloroquine/hydroxychloroquine
(data not shown).
DISCUSSION
The hypothalamus-pituitary-liver-muscle (HPLM) axis is a
delicate reflex loop stabilising muscle mass (fig 3): the liver,
upon stimulation with growth hormone, produces IGF1,
IGF1 stimulates muscle growth, and IGF1 itself inhibits its
own secretion from the liver.18 IGF1 induced inhibition of
liver IGF1 is probably dependent on consumption of liver
IGF1 within the muscle (binding to receptors and local
degradation). Both TNF and exogenous glucocorticoids
inhibit muscle growth by stimulating protein degradation
pathways in the muscle and by interfering with IGF1
signalling (fig 3).19–21 Glucocorticoids exert an additional
inhibiting effect on muscle by inducing the muscle growth
inhibiting factor myostatin.22 One study in burn induced
muscle degradation showed that exogenous and endogenous
glucocorticoids induce myostatin.22 Furthermore, it was
shown that glucocorticoids inhibit the production of muscle
IGF1, leading to a decrease in negative feedback regulation of
liver IGF1 (fig 3).23 The decrease in negative feedback would
increase serum levels of IGF1 (fig 3).
In addition, TNF inhibits growth hormone induced IGF1
production from the liver.9 24 25 We have not tested serum
levels of growth hormone, a decrease in which might cause
low serum levels of IGF1 (as observed). Such a decrease in
growth hormone would be an unwanted effect of high TNF
levels, which could add to the negative sequelae of
rheumatoid arthritis, such as atherosclerosis and raised
serum lipids. However, as growth hormone kinetics are not
notably changed in rheumatoid patients in general,26 the
effect is likely to be dependent on a mechanism other than
growth hormone secretion and action in the liver. In
addition, because exogenous glucocorticoids inhibit pituitary
growth hormone release,27 one would have expected low
levels of growth hormone stimulated IGF1 in patients with
prednisolone treatment. However, exactly the opposite was
observed, refuting a marked influence of growth hormone on
the observed phenomena.
In patients with rheumatoid arthritis, TNF plays a
dominant proinflammatory role, and affected individuals
are often treated with exogenous glucocorticoids (as in the
ReAct study). In such patients, therefore, two important
muscle growth inhibiting factors are present which may have
a major influence on muscle homeostasis (fig 3). This is adds
to the disability suffered by these patients and contributes to
rheumatoid cachexia.28 Our study shows that neutralisation
of TNF by anti-TNF therapy decreases serum IGF1 in patients
receiving glucocorticoids (in the presence of somewhat raised
myoglobin levels). It is possible that our patients who were
on prednisolone were more ill than those not receiving
prednisolone, which may have resulted in increased myoglo-
bin levels. However, this was not supported by the baseline
characteristics given in table 1. It is noteworthy that
myoglobin did not change during anti-TNF treatment, but
this may depend on other proinflammatory factors and
longstanding effects on muscle degradation. Removal of the
important proinflammatory agent TNF will probably attenu-
ate muscle wasting by increasing IGF1 effects (after removal
of IGF1 resistance). We did not test muscle strength during
the treatment but it is thought that muscle function improves
during anti-TNF therapy, as indicated by improved scores on
the Health Assessment Questionnaire.13 Positive effects of
TNF neutralising strategies on growth rates have been
described in children with juvenile idiopathic arthritis.29 In
addition, positive effects of improved IGF1 signalling on TNF
induced cartilage degradation are also expected.7 8
Our two patients groups—with and without glucocorticoid
treatment—were different in age, which may have influenced
Figure 3 The hypothalamus-pituitary-liver-muscle (HPLM) axis. Growth
hormone releasing hormone (GHRH) from the hypothalamus stimulates
pituitary growth hormone (GH) release. GH stimulates insulin-like
grwoth factor 1 (IGF1) production from the liver. Liver IGF stimulates
muscle growth directly and by inducing muscular IGF1 (1). Tumour
necrosis factor (TNF) and exogenous glucocorticoids inhibit effects of
liver IGF1 and local IGF1 on muscle growth (2). TNF and glucocorticoids
increase protein degradation in the muscle. Consumption of liver IGF1
and downregulation of local IGF1 decrease the negative feedback signal
to the liver (3). In patients with glucocorticoids, this leads to a loss of the
negative feedback signal to the liver and thus to an increase of liver IGF1
measurable in the serum. The question mark stands for other unknown
muscle factors additionally involved in the negative feedback to the liver.
IGF1 itself inhibits GHRH release (4), which is also inhibited by
endogenous and exogenous glucocorticoids. Musc., muscle.
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our results. Patients on prednisolone were on average 10
years older than those not receiving glucocorticoids. As IGF1
levels decrease with aging,30 one would have expected a lower
serum IGF1 in the older patients (who were also more likely
to be on prednisolone). However, we observed exactly the
opposite, with increased IGF1 levels in these patients, which
is additional evidence of IGF1 resistance.
Furthermore, the observed effects of anti-TNF are most
probably independent of IGF1 binding proteins because
serum IGFBP-1 and IGFBP-2 did not change during treat-
ment. In this study, we observed a positive correlation
between serum IL6 and serum IGFBP-1, which confirms a
positive influence of IL6 on the synthesis of these binding
proteins.31
Conclusions
Our study suggests an attenuation of IGF1 resistance in
steroid treated patients with rheumatoid arthritis who are
also receiving an anti-TNF therapy. This may be an important
new favourable effect of anti-TNF treatment in such patients.
Future studies in larger samples over a longer period of time
should address whether or not anti-TNF therapy increases
both muscle mass (as measured, for example, by magnetic
resonance imaging) and muscle strength on clinical testing.
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